Key Points
- Insider purchase: Oliver Engert acquired 1,000 Enovis shares at $25.50 on Feb. 27 for $25,500, increasing his stake to 43,640 shares (a 2.35% rise), per an SEC filing.
- Quarterly results: Enovis posted $0.95 EPS vs. $0.81 expected (beat) but revenue of $575.8M missed the $584.3M estimate and the company recorded a negative net margin of 52.69%; management set FY2026 EPS guidance of 3.520–3.730.
- Market and analyst view: Shares opened down ~1.2% with a $1.45B market cap and 98.45% institutional ownership, and analysts mostly rate the stock a "Buy" with a consensus price target of $47.43.
Enovis Corporation (NYSE:ENOV - Get Free Report) insider Oliver Engert acquired 1,000 shares of Enovis stock in a transaction that occurred on Friday, February 27th. The shares were purchased at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the purchase, the insider directly owned 43,640 shares in the company, valued at $1,112,820. The trade was a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Enovis Stock Down 1.2%
Shares of NYSE:ENOV opened at $25.39 on Wednesday. The company has a 50 day moving average price of $24.23 and a two-hundred day moving average price of $28.12. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The company has a market capitalization of $1.45 billion, a PE ratio of -1.23 and a beta of 1.46. Enovis Corporation has a 52 week low of $21.00 and a 52 week high of $40.69.
Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The company had revenue of $575.76 million for the quarter, compared to analysts' expectations of $584.30 million. During the same period last year, the firm posted $0.98 earnings per share. The business's quarterly revenue was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts forecast that Enovis Corporation will post 2.79 earnings per share for the current year.
Institutional Investors Weigh In On Enovis
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Arax Advisory Partners acquired a new stake in shares of Enovis in the fourth quarter valued at about $29,000. Farther Finance Advisors LLC grew its stake in Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company's stock valued at $37,000 after purchasing an additional 367 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock worth $40,000 after purchasing an additional 707 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new position in shares of Enovis in the second quarter valued at $46,000. Finally, SJS Investment Consulting Inc. increased its holdings in Enovis by 30,340.0% during the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company's stock worth $46,000 after buying an additional 1,517 shares during the last quarter. 98.45% of the stock is owned by institutional investors.
Analyst Ratings Changes
ENOV has been the topic of a number of research analyst reports. BTIG Research raised their price target on Enovis from $41.00 to $43.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Needham & Company LLC upped their price target on shares of Enovis from $49.00 to $52.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Wells Fargo & Company boosted their price objective on shares of Enovis from $41.00 to $42.00 and gave the company an "overweight" rating in a research report on Friday, November 7th. Canaccord Genuity Group lowered their target price on Enovis from $58.00 to $50.00 and set a "buy" rating for the company in a report on Wednesday, December 17th. Finally, UBS Group reaffirmed a "buy" rating and set a $50.00 price objective on shares of Enovis in a research report on Monday, January 5th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $47.43.
View Our Latest Report on Enovis
Enovis Company Profile
(
Get Free Report)
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
